Ruiz-Delgado GJ, Fernández-Macouzet M, Alarcón-Urdaneta C, Ruiz-Argüelles GJ

Language: English
References: 13
Page: 39-41
PDF size: 57.59 Kb.

ABSTRACT

The case of a patient with multiple myeloma is presented. She was autografted after achieving a complete remission and had a relapse while being followed without maintenance treatment 28 months after the graft. Once achieving a second remission she was re-autografted and subsequently given maintenance treatment with oral thalidomide, the patient remaining in a sustained stringent complete remission for a period of over 55 months. Information about the role of maintenance therapy in myeloma patients after achieving a remission stems mainly from trials comparing patients who have or not received thalidomide as maintenance therapy. Since the only difference between the two autografts was that in the second one maintenance with oral thalidomide was employed, this case clearly shows that it was the responsible for the long-lasting remission observed in the patient after the second autograft.

REFERENCES

1. Ruiz-Delgado GJ, Ruiz-Argüelles GJ. El trasplante autólogo sigue siendo importante en el tratamiento del mieloma mútiple. Rev Hematol Mex 2011;12(Suppl 1):S1-S2.

2. Gómez-Almaguer D, Cano-Castellanos R, Cedillo-de la Cerda JL, Garcés-Ruíz O, Limón-Flores A, y col. Guías mexicanas de diagnóstico y recomendaciones terapéuticas para mieloma múltiple (2009). Rev Hematol Mex 2010;11:40-62.

3. Kyle RA. Diagnosis and treatment of multiple myeloma in 2010. Rev Hematol Méx 2010;11:30-39.

4. López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: A single institution experience. Bone Marrow Transplant 2009;44:715-719.

5. Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2011. Oct 20. [Epub ahead of print].

6. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3286-3294.

7. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic- cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-1030.

8. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788-1793.

9. Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010;115:1113-1120.

10. Sahebi F, Spielberger F, Kogut NM, et al. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 2006;37:825-829.

11. Hicks LK, Haynes AE, Reece DE, et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008;34:442-452.

12. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel I. Blood 2011; 117:4691-4695.

13. Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Lenalidomide maintains remissions in persons with multiple myeloma intolerant to thalidomide. Rev Hematol Mex 2011;12:79-81.